Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Longitudinal analysis of lung cancer-specific immunity in advanced non-small cell lung cancer
NL-OMON25535Not yet recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Oct 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of crizotinib, gefitinib and erlotinib in non-small cell lung cancer (NSCLC), sponsored by Netherlands Cancer Institute. Planned start Oct 2012; status: not yet recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON25535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON25535.